New treatments for COPD.
COPD is one of the most common diseases in the world, and there is a global increase in prevalence, but there are no drugs available at present that halt the relentless progression of this disease. However, a better understanding of the cellular and molecular mechanisms that are involved in the underlying inflammatory and destructive processes has revealed several new targets for which drugs are now in development, and the prospects for finding new treatments are good.
National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK. p.j.barnes@ic.ac.uk
Peter J
PJ
Barnes
D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors; D016753:Interleukin-10 / Q000627:therapeutic use; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000209:etiology; D016540:Smoking Cessation; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D001993:Bronchodilator Agents; D018836:Inflammation Mediators; D016328:NF-kappa B; D011480:Protease Inhibitors; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10